LA
JAZZ icon

Linden Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Linden Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-4,700
Closed -$660K – 85
2015
Q4 		$660K Buy
+4,700
New +$651K 0.04% 63

Other funds holding JAZZ

PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Linden Advisors's JAZZ Position: Q1 2016 in Review

Linden Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2016, closing a stake of 4,700 shares — an estimated $660K sold.

Linden Advisors first reported a position in JAZZ in Q4 2015 and held it in 1 quarter. The position peaked at $660K in Q4 2015. 339 funds tracked by Wall St. Rank hold JAZZ as of Q1 2016.

  • Linden Advisors reported no remaining Jazz Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Linden Advisors sold 4,700 Jazz Pharmaceuticals shares in Q1 2016, an estimated $660K.
  • Linden Advisors first reported a position in Jazz Pharmaceuticals in Q4 2015 and held it in 1 quarter.
  • Linden Advisors's Jazz Pharmaceuticals position peaked at $660K in Q4 2015.
  • 339 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2016.

Based on Linden Advisors's 13F filing for Q1 2016, filed 16 May 2016.